FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
RUBY Financial Statements
Quarter
2022 Q4
2022 Q3
2022 Q2
2022 Q1
Total Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
1.95M
31.53M
42.91M
50.86M
Research and Development
888k
24.23M
33M
38.3M
Selling, General & Administrative Expenses
1.06M
7.3M
9.91M
12.56M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
1.06M
7.3M
9.91M
12.56M
Other Expenses
1.7M
53k
40k
31k
Operating Income
-127k
-61.58M
-42.91M
-50.86M
Total Other Income/Expenses Net
-20.01M
-1.29M
-1.33M
-1.55M
Income Before Tax
-20.14M
-62.87M
-44.24M
-52.41M
Income Tax
21.14M
30.05M
1.33M
1.55M
Net Income
-41.28M
-92.92M
-45.58M
-53.96M
Basic EPS
-0.46
-1.03
-0.5
-0.6
EPS Diluted
-0.46
-1.03
-0.5
-0.6
Basic Average Shares
90.43M
90.36M
90.26M
90.15M
Diluted Average Shares
90.43M
90.36M
90.26M
90.15M
EBITDA
-28.62M
-61.58M
-41.01M
-49.22M
All figures are in USD.
